RESHAPE LIFESCIENCES INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1701 USD | +1.19% |
|
-0.35% | -31.88% |
| Apr. 12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
| Apr. 01 | Transcript : ReShape Lifesciences Inc., Q4 2023 Earnings Call, Apr 01, 2024 |
Financials (USD)
| Sales 2024 * | 9.99M | Sales 2025 * | 11.99M | Capitalization | 3.94M |
|---|---|---|---|---|---|
| Net income 2024 * | -6M | Net income 2025 * | -5M | EV / Sales 2024 * | 0.39 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.33 x |
| P/E ratio 2024 * |
-0.37
x | P/E ratio 2025 * |
-0.47
x | Employees | 29 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.83% |
More Fundamentals
* Assessed data
More news
Latest transcript on ReShape Lifesciences Inc.
More recommendations
More press releases
| 1 day | +1.73% | ||
| 1 week | +1.93% | ||
| Current month | -5.64% | ||
| 1 month | -7.50% | ||
| 3 months | -14.33% | ||
| 6 months | -30.40% | ||
| Current year | -30.32% |
1 week
0.17
0.18
1 month
0.160.21
Current year
0.140.30
1 year
0.142.80
3 years
0.14475.00
5 years
0.14738.00
10 years
0.141 000 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Paul Hickey
CEO | Chief Executive Officer | 59 | 20-01-31 |
| Director of Finance/CFO | 63 | 21-06-14 | |
Dov Gal
CMP | Compliance Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gary Blackford
BRD | Director/Board Member | 66 | 15-12-31 |
Dan Gladney
CHM | Chairman | 70 | 15-10-31 |
| Director/Board Member | 70 | 21-06-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 0.1701 | +1.19% | 12 923 |
| 24-04-24 | 0.1681 | -1.41% | 117,465 |
| 24-04-23 | 0.1705 | +2.16% | 180,674 |
| 24-04-22 | 0.1669 | +0.97% | 103,794 |
| 24-04-19 | 0.1653 | -3.16% | 79,632 |
Delayed Quote Nasdaq, April 25, 2024 at 09:34 am EDT
More quotes
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Calendar
2024-05-19
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.1681
USD
Average target price
1
USD
Spread / Average Target
+494.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -30.32% | 3.94M | |
| +8.44% | 220B | |
| +7.63% | 185B | |
| +10.33% | 133B | |
| +26.53% | 107B | |
| -0.15% | 62.91B | |
| +14.85% | 53.34B | |
| -1.63% | 47.71B | |
| -2.09% | 40.29B | |
| +11.65% | 39.57B |
- Stock Market
- Equities
- RSLS Stock
